About 17 percent of the faculty members at MD Anderson Cancer Center signed a petition that disagreed with the institution’s Faculty Senate in its efforts to step in and improve morale at the Houston-based institution.
A group of melanoma experts, joined by three advocacy groups focused on melanoma, has engaged FDA in a public discussion of the challenges of developing new drugs in the refractory setting and the role crossover can play in such trials.
